Syntara Limited has released a press release.
Quarterly Activity Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Syntara
- Appendix 4C - quarterly
- Sale of Russian Distribution Rights
- First Patient Enrolled - Clinical Trial for Cancer Treatment
- Pharmaxis Exports CF Drug to US - US$3 Million Milestone
- Quarterly Activity Report - December 2020
Later from Syntara
- PXS Announces First Results in Bone Marrow Cancer Trial
- PXS Sells Australian Distribution Rights for A$2m
- PXS Drug Decreases Tumour Burden in Liver Cancer Model
- PXS Grants Exclusive Option to Develop High Payload Inhaler
- Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara